Product Information
ADALIMUMAB-AACF(CF) PEN 40 MG/0.8 ML (2 PACK) is a generic product labeled by Fresenius Kabi USA, LLC, priced at $872.7167 per EA under NDC 65219061299. Its NADAC has been published 68 times since Jun 18, 2025.
Manufacturer
Fresenius Kabi USA, LLCNDC
65219061299
Classification
Generic
Dosage Form
KIT
Route
SUBCUTANEOUS
Effective Date
9/23/2026
Approval Type
Biologic (BLA)
FDA Application
BLA761255On Market Since
12/6/2023
Price Statistics
The NADAC for ADALIMUMAB-AACF(CF) PEN 40 MG/0.8 ML (2 PACK) has been published 68 times since Jun 18, 2025, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $872.7167 per EA |
|---|---|
| All-time high | $873.7122 (Jul 15, 2026) |
| All-time low | $871.4500 (Jun 18, 2025) |
| 52-week high | $873.7122 |
| 52-week low | $872.2928 |
| Median price | $872.7719 |
| Average price | $872.6623 |
| Largest weekly change | -0.1% (Aug 19, 2026) |
| Weeks tracked | 68 |
| Tracking since | Jun 18, 2025 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the adalimumab market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Fresenius Kabi USA, LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
adalimumab market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ADALIMUMAB-AACF(CF) PEN 40 MG/0.8 ML (2 PACK)?
The current National Average Drug Acquisition Cost (NADAC) for ADALIMUMAB-AACF(CF) PEN 40 MG/0.8 ML (2 PACK), manufactured by Fresenius Kabi USA, LLC, is $872.7167 per EA (NDC 65219061299), effective Sep 30, 2026.
How has the price of ADALIMUMAB-AACF(CF) PEN 40 MG/0.8 ML (2 PACK) changed over time?
Over the history we have for it, the NADAC for ADALIMUMAB-AACF(CF) PEN 40 MG/0.8 ML (2 PACK) has held within roughly two percent of its current level. It has been tracked across 68 weekly CMS publications since Jun 18, 2025.
What are the highest and lowest recorded NADAC prices for ADALIMUMAB-AACF(CF) PEN 40 MG/0.8 ML (2 PACK)?
Since Jun 18, 2025, the NADAC for ADALIMUMAB-AACF(CF) PEN 40 MG/0.8 ML (2 PACK) has ranged from a low of $871.4500 (Jun 18, 2025) to a high of $873.7122 (Jul 15, 2026), with a median of $872.7719 per EA.
Are there cheaper alternatives to ADALIMUMAB-AACF(CF) PEN 40 MG/0.8 ML (2 PACK)?
No other NADAC-published product currently shares the active ingredient and strength of ADALIMUMAB-AACF(CF) PEN 40 MG/0.8 ML (2 PACK) in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ADALIMUMAB-AACF(CF) PEN 40 MG/0.8 ML (2 PACK)?
ADALIMUMAB-AACF(CF) PEN 40 MG/0.8 ML (2 PACK) (NDC 65219061299) is labeled by Fresenius Kabi USA, LLC, and CMS classifies it as a generic product.